Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Mixture of rare ginsenoside and application of mixture

A technology of ginsenosides and mixtures, applied in the field of mixtures of rare ginsenosides, can solve the problems of poor prognosis, poor differentiation of malignant tumors, rapid progress and the like, achieve broad application prospects and enhance the effect of anti-tumor effects

Active Publication Date: 2018-09-28
SHENZHEN YINUO BIOPHARM CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Malignant tumors with high expression of HIF-1α are mostly poorly differentiated, progress rapidly, have high angiogenesis density, are prone to metastasis and recurrence, and have poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mixture of rare ginsenoside and application of mixture
  • Mixture of rare ginsenoside and application of mixture
  • Mixture of rare ginsenoside and application of mixture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1 Rare ginsenoside YNPD2 promotes the ubiquitination and degradation of HIF-1α (hypoxia-inducible factor 1α) and resists hypoxia

[0122] 1. Cell treatment

[0123] Liver cancer PLC cells in good growth state were inoculated into 96-well cell culture plates and placed in CO 2 Culture in an incubator at 37°C. On the next day, when the cells reached 70-80% confluence, the drug was added, and after the drug was added, the culture plate was returned to the incubator for cultivation at 37°C. This experiment was divided into 4 groups, namely control group, hypoxia (Hypoxiα) group, rare ginsenoside YNPD2 + hypoxia (Hypoxiα) group. The specific method is as follows: the control group is not treated, and the culture medium is replaced every 1-2 days; the hypoxia group is added with 150 μM cobalt chloride solution in the culture medium to simulate the hypoxic environment; the YNPD2+ hypoxia group is added with 150 μM cobalt chloride solution in the culture medium at the...

Embodiment 2

[0140] Example 2 Rare ginsenoside monomers have a regulatory effect on tumor glucose metabolism

[0141] 1. Materials and instruments

[0142] (1) Human liver cancer cell line

[0143] HepG2 (human liver cancer cell line): purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.

[0144] (2) Test product

[0145] Eleven kinds of rare ginsenosides (YNPD1, YNPD2, YNPT1, YNPT2, YNH2, YNH3, YNG3, YNG5, YNPD, YNPT and YNK1) were provided by Royal Enoch Phytopharmaceuticals Co., Ltd. of Canada.

[0146] (3) Experimental reagents

[0147] Dimethyl sulfoxide (DMSO) cell culture grade: purchased from Beijing Suolaibao Technology Co., Ltd., article number: D8370-500, batch number: 2P005970, grade: cell culture grade, specification 500mL, used for cell cryopreservation, and drug preparation .

[0148] DMEM medium (low sugar): purchased from Thermo Fisher Scientific Co., Ltd., Hyclone brand, product number: 11885092, specification: 500 mL.

[0149] DMEM medium (sugar-free): ...

Embodiment 3

[0193] In order to further illustrate the beneficial effects of the present invention, the combination of 11 kinds of rare ginsenosides and pentose phosphate pathway inhibitor 6-AN has a regulating effect on tumor glucose metabolism. Specifically, using the experimental conditions determined in the above experiments, the experiments were divided into 6 large groups:

[0194] A. Add the drug immediately after changing the normal medium to low-glucose medium;

[0195] B. Add drugs after pre-cultivation in low-sugar medium for 6 hours;

[0196] C. Add drugs after pre-cultured in low-sugar medium for 12 hours;

[0197] D. Add the drug immediately after changing the normal medium to a sugar-free medium;

[0198] E. Drugs were added after pre-cultured in sugar-free medium for 6 hours;

[0199] F. Drugs were added after pre-cultured in sugar-free medium for 12 hours.

[0200] Each of the above groups is divided into 3 groups: 1. The effect of rare ginsenosides alone; 2. The effec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a mixture of rare ginsenoside and application of the mixture. The mixture of rare ginsenoside comprises rare ginsenoside and a pentose metabolic pathway inhibitor. A rare ginsenoside monomer promotes ubiquitination and degradation of HIF-1alpha (hypoxia-inducible factor-1alpha) through proteasome; the content of the HIF-1alpha in a tumor cell is lowered, theoretically, tumor glycometabolism pathways including pentose-phosphate pathways can be inhibited, and thus the anti-tumor effect is achieved. According to the mixture of rare ginsenoside and the application of the mixture, it is innovatively achieved that the rare ginsenoside monomer and a pentose-phosphate pathway inhibitor 6-amidogen nicotinamide (6-AN) are jointly applied in vitro to act on a hepatoma cell line (HepG2), and the rare ginsenoside monomer and the pentose-phosphate pathway inhibitor 6-amidogen nicotinamide (6-AN) have an obvious synergistic anticancer effect. Therefore, rare ginsenoside and atumor glycometabolism pathway inhibitor which have the effect of regulating glycometabolism pathways are jointly applied to strengthening the anti-tumor effect of the mixture, and the mixture is usedfor therapy of malignant tumors and has a wide application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a mixture of rare ginsenosides and its application. Background technique [0002] Cancer has a high morbidity and mortality rate worldwide, which seriously threatens human health. Cancer is so harmful and difficult to overcome because of the unique characteristics of its own malignant tumor cells, namely, continuous angiogenesis, growth mode with unlimited energy acquisition, resistance to apoptosis, unlimited replication ability, escape from immune destruction, tissue infiltration and transfer characteristics. Its abnormal energy metabolism has attracted more and more attention and has become a new target for tumor therapy. For cells, energy mainly comes from glucose metabolism, and glucose is the main energy source for cellular glucose metabolism. Under ideal conditions in normal cells, glucose enters the cell through the glucose transporter (GlUT), and through the decomposition of a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/704A61K31/575A61K31/455A61P35/00A61P35/02
CPCA61K45/06A61P35/00A61P35/02A61K31/455A61K31/575A61K31/704
Inventor 余佩华孙涛李安平
Owner SHENZHEN YINUO BIOPHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com